This is not just another shareholder revolt.
Mylan, which sells EpiPen, holds its annual shareholder meeting in the Netherlands on Thursday. And several large pension funds are working publicly — and also behind the scenes — to push out key directors, starting with Robert Coury, the controversial non-executive chairman, and Heather Bresch, the chief executive officer.
But much more is at stake than unhappy investors.
About the Author Reprints
